INOZYME PHARMA INC (INZY)
US45790W1080 - Common Stock
INOZYME PHARMA INC
NASDAQ:INZY (4/29/2024, 1:06:28 PM)
4.405
-0.04 (-0.79%)
Company Profile
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2020-07-24. The firm is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The firm is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies. Its INZ-701 is in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 is designed to increase circulating levels of plasma pyrophosphate (PPi), and adenosine.
Company Info
INOZYME PHARMA INC
321 Summer Street, Suite 400
Boston MASSACHUSETTS 02210
P: 18573304340
CEO: Axel Bolte
Employees: 56
Website: https://www.inozyme.com/
INZY News
21 days ago - Inozyme Pharma Inc.Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) -
24 days ago - Inozyme Pharma Inc.Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical...
a month ago - Inozyme Pharma Inc.Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceBOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease...
INZY Twits
Here you can normally see the latest stock twits on INZY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
